Company Overview of Maxim Pharmaceuticals Inc.
As of January 4, 2006, Maxim Pharmaceuticals Inc. was acquired by EpiCept Corporation. Maxim Pharmaceuticals, Inc., a biopharmaceutical company, develops cancer therapeutics. Its lead drug candidate, Ceplene, is in a phase III clinical trial as a remission maintenance therapy for patients with acute myeloid leukemia, a form of adult leukemia. The company’s Apoptosis drug is under preclinical trial; and MX8899, which is in phase I and II clinical trials for oral mucositis and radiation dermatitis. Maxim also has Ceplene for chronic liver disease under phase I and phase II clinical trials. Ceplene prevents or reverses damage associated with oxidative stress, thereby protecting critical cells a...
8899 University Center Lane
San Diego, CA 92122
Founded in 1954
Key Executives for Maxim Pharmaceuticals Inc.
Maxim Pharmaceuticals Inc. does not have any Key Executives recorded.
Maxim Pharmaceuticals Inc. Key Developments
EpiCept Corporation Together with its Wholly-Owned Subsidiaries Maxim Pharmaceuticals Inc. and Cytovia, Inc., Enter into a Second Amendment to Loan and Security Agreement with MidCap Funding III, LLC
Aug 1 13
EpiCept Corporation together with its wholly-owned subsidiaries Maxim Pharmaceuticals Inc. and Cytovia Inc., entered in to a second amendment to loan and security agreement with MidCap Funding III, LLC, as agent for the lenders. Under the amendment, the company will continue to make monthly payments of interest to the lender as per the loan and security agreement and one half of the cash that is subject to the security interest maintained by MidCap will be returned to the company upon the favorable stockholder vote to approve the final conditions to the closing of the merger. Any past defaults under the loan agreement have been waived and principal payments on the loan are scheduled to begin September 1, 2013 unless a restructuring of the loan has been executed.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries